EP221: Professor David Colquhoun on The Cholesterol Debate

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Podcast Summary Introduction: Dr. Warrick Bishop, a practicing cardiologist and author dedicated to patient education about heart health, hosts this episode featuring Associate Professor David Cahoon, co-president of the Prevention Arm of the Cardiac Society of Australia and New Zealand. The episode discusses a recent debate about the scientific validity of cholesterol management and statin therapy, with Dr. Cahoon representing the evidence-based medical perspective against three prominent figures who challenged conventional cholesterol treatment. Key Takeaways: The "Catalyst" program featuring Marianne de Massey, a non-expert journalist, promoted medically harmful misinformation that led to increased heart attacks, strokes, and mortality when viewers stopped taking statins—demonstrating the dangers of poor science reporting. Ross Walker's claim that only 1 in 19 people need statins lacks scientific evidence and contradicts established research showing that for every 1 millimole reduction in LDL cholesterol, there is a 25% reduction in heart attacks and 20% reduction in strokes. Claims that cholesterol is needed for hormone production misunderstand basic biochemistry; while cholesterol is used for hormones, the body produces excess cholesterol in every cell, and HDL removes waste LDL particles back to the liver for recycling. LDL particles are waste products from the liver's transport of triglycerides and become atherosclerotic only when modified (oxidized, glycosylated) or when inflammation increases endothelial permeability, making lowering LDL levels a valid therapeutic target. Dr. Chaffee, a neurosurgical registrar and bodybuilder without lipid metabolism expertise, inappropriately positioned himself as a cholesterol expert and misquoted the Framingham study, claiming it showed low cholesterol increased coronary artery disease. Inflammation, while an important factor in atherosclerosis, is not the sole driver of plaque formation; over 60 risk factors exist, with five key ones including smoking, anxiety, and depression that increase LDL atherogenicity. Major clinical trials like the Australian Lipid Trial involved independent safety and data monitoring committees that were not corrupt despite pharmaceutical funding; the funding simply covered operational costs, not individual compensation. The Australian MIPA trial was the first in the world to demonstrate that lowering LDL by one millimole per litre decreased total mortality by 3% over six years in patients with average cholesterol levels. Critics like Dr. Malhotra who lack research involvement themselves question the integrity of researchers while offering no independent data, contradicting evidence-based standards. Contemporary statin therapy targets require at least 2 millimole per litre LDL reduction to be considered adequate treatment, and cholesterol discussion should focus on LDL particles rather than general "cholesterol" terminology.